CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy and safety of certolizumab pegol therapy for 26 weeks in an unselected Crohn's disease population: Results of the FACTS II survey
DOI 10.1055/s-0030-1263685
Bibliografische Angaben
Nachweis in CareLit
Autor:innenSR Vavricka, A Schöpfer, G Bansky, J Binek, C Felley, M Geyer, M Manz, G Rogler, P de Saussure, B Sauter, M Scharl, F Seibold, A Straumann, P Michetti
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background and Aims: Certolizumab pegol (Cimzia CZP) was approved for the treatment of Crohn's disease (CD) patients in 2007 in Switzerland as first country worldwide. This prospective phase IV study aimed to evaluate the efficacy and safety of CZP over 26 weeks in a multicenter cohort of practice-based patients. Methods: Evaluation questionnaires at baseline, week 6 and 26 were completed by gastroenterologists in h…
Zitieren
Zitierempfehlung
SR Vavricka, A Schöpfer, G Bansky, J Binek, C Felley, M Geyer, M Manz, G Rogler, P de Saussure, B Sauter, M Scharl, F Seibold, A Straumann, P Michetti (2010) Efficacy and safety of certolizumab pegol therapy for 26 weeks in an unselected Crohn's disease population: Results of the FACTS II survey. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0030-1263685
Mit CareLit weiterarbeiten